Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology-Clinical Diagnosis: Neuroendocrine

Somatostatin receptor expression in metastatic NET lesions depends on primary tumor site

Stefan Kaeshammer, Matthias Miederer, C. Fottner, M. Weber and Mathias Schreckenberger
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1259;
Stefan Kaeshammer
1Dept. of Nuclear Medicine, University Medical Center, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Miederer
1Dept. of Nuclear Medicine, University Medical Center, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Fottner
2Dept. of Endocrinology, University Medical Center, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Weber
2Dept. of Endocrinology, University Medical Center, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Schreckenberger
1Dept. of Nuclear Medicine, University Medical Center, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1259

Objectives In patients with neuroendocrine tumors (NET) 68Ga-DOTA-Tyr-octreotide (DOTATOC)-PET/CT is a tool of growing importance for tumor-detection, therapy planning and control. Even though the somatostatin receptor expression can be relatively quantified using standard uptake values (SUV), just few trials have so far aimed to determine characteristic ranges for SUV in primary and metastatic NET-lesions of specific localisations. We present a descriptive analysis of SUV ranges in NET and their metastases.

Methods Ga68-DOTATOC-PET/CT-Scans of 80 Patients with metastasised NET of the small bowel (38%), pancreas (20%), lung (11%) or other/unknown primary (31%) were analysed retrospectively. SUVmax in metastatic lesions was compared to SUVmax of the primary tumor site. We furthermore correlated SUVmax of the primary tumor lesions to SUVmax in the organ-specific metastatic lesions.

Results SUVmax of metastatic lesions was significantly higher in pancreatic NET (20.9; n=11) than in NET of the small bowel (16.7; n=54). Mean SUVmax in liver-metastasis was 20.5 (SD 19.1; range 5.1 - 64.4) and 18.7 (SD 18.1; range 3.2 - 59.9) in the corresponding primary tumor site. In lymph node metastases we observed a mean SUVmax of 13.0 (SD 10.2; range 1.9 - 28.1) and 14.3 (SD 6.8; range 6 - 25.4) in the corresponding primary tumor site. A significant correlation between SUVmax in organ-specific metastases and in primary NET was found in patients with liver-metastases and in lymph node metastases.

Conclusions In this retrospective study metastatic NET lesions showed higher SUV values in pancreatic NET than in bowel NET with the SUV in metastatic lesions closely correlated to the primary tumor SUV. Since SUV values represent the somatostatin receptor expression on NET-cells, these findings might be used in the future for response prediction of radiopeptide therapy in metastasised NET. Further prospective studies should be carried out to confirm our findings

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 51, Issue supplement 2
May 2010
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Somatostatin receptor expression in metastatic NET lesions depends on primary tumor site
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Somatostatin receptor expression in metastatic NET lesions depends on primary tumor site
Stefan Kaeshammer, Matthias Miederer, C. Fottner, M. Weber, Mathias Schreckenberger
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1259;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Somatostatin receptor expression in metastatic NET lesions depends on primary tumor site
Stefan Kaeshammer, Matthias Miederer, C. Fottner, M. Weber, Mathias Schreckenberger
Journal of Nuclear Medicine May 2010, 51 (supplement 2) 1259;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology-Clinical Diagnosis: Neuroendocrine

  • Glucagon-like peptide-1 vs. somatostatin receptor targeting in malignant insulinoma
  • Detection of intestinal NET by (68)Ga-DOTATOC PET/multiphase CT
Show more Oncology-Clinical Diagnosis: Neuroendocrine

Neuroendocrine Posters

  • Physiological uptake of 68Ga-DOTA-NOC in the head of the pancreas in patients with NET
  • Comparison of 18F-FDG PET and 99mTc-TOC scintigraphy in patients with neuroendocrine tumor
  • Detection of intestinal NET by (68)Ga-DOTATOC PET/multiphase CT
Show more Neuroendocrine Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire